Science-driven and patient-focused
Targeting inflammation to boldly transform the lives of patients with severe neurological diseases
Pipeline
Our product pipeline and areas of focus
| Product | Indication | Pre-Clinical | Phase 1/2 | Phase 3 | NDA |
|---|---|---|---|---|---|
EGT 101 |
Delayed cerebral ischemia |
Egret therapeutics
|
|
|
|
Ischemic stroke |
Egret therapeutics
|
|
|
|
|
EGT 102 |
Glioblastoma |
Egret therapeutics
|
|
|
|
Brain metastasis |
Egret therapeutics
|
|
|
|
EGT 101
Using immune regulating pathways to reduce permanent brain aneurysm damage
Research shows that the same highly specific and powerful immune regulating pathways used by tumors can be leveraged to prevent DCI by precisely targeting the responsible inflammatory cells.
Team
Visionary leadership with deep experience in research and drug development
Leadership
Dan Chai, MD
Chief Executive Officer
Chris Jackson, MD
Co-Founder & Chief Medical Officer
PRIYA JAMBHEKAR, PhD
Chief Regulatory Officer
XIAOBU YE, MD, MS
Chief Clinical Development Officer
HENRY PARK
Chief Financial Officer
FRANK BORCHETTA
General Counsel
Advisory Board
MICHAEL LIM, M.D.
Co-Founder & Chair of Advisory Board
